Henrik Jungaberle1, Sascha Thal2, Andrea Zeuch3, Ansgar Rougemont-Bücking4, Maximilian von Heyden5, Helena Aicher6, Milan Scheidegger7. 1. MIND European Foundation for Psychedelic Science, betahaus, Prinzessinnenstr. 19/20, 10969 Berlin, Germany. Electronic address: Henrik.Jungaberle@mind-foundation.org. 2. Faculty of Behavioural and Social Sciences, University of Groningen, Netherlands, Grote Kruisstraat 2/1, 9712 TS Groningen, the Netherlands. Electronic address: S.B.Thal@student.rug.nl. 3. MIND European Foundation for Psychedelic Science, betahaus, Prinzessinnenstr. 19/20, 10969 Berlin, Germany. Electronic address: Andrea.Zeuch@mind-foundation.org. 4. Faculty of Science and Medicine, Department of Neurosciences and Movement Science, Laboratory for Psychiatric Neuroscience and Psychotherapy, University of Fribourg, Ch. du Musée 5, Fribourg, Switzerland. Electronic address: Ansgar.Rougemont-Buecking@unifr.ch. 5. FINDER Institute for Prevention Research, Germany, betahaus, Prinzessinnenstr. 19/20, 10969 Berlin, Germany. Electronic address: Maximilian.vonHeyden@finder-research.com. 6. Neuropsychopharmacology and Brain Imaging, Department of Psychiatry, Psychotherapy and Psychosomatics (DPP), University Hospital of Psychiatry Zurich, Lenggstrasse 31, Postfach 1931, CH-8032 Zurich, Switzerland. Electronic address: Helena.Aicher@mind-foundation.org. 7. Neuropsychopharmacology and Brain Imaging, Department of Psychiatry, Psychotherapy and Psychosomatics (DPP), University Hospital of Psychiatry Zurich, Lenggstrasse 31, Postfach 1931, CH-8032 Zurich, Switzerland. Electronic address: Milan.Scheidegger@bli.uzh.ch.
Abstract
RATIONALE: We reviewed the concepts and empirical findings in studies with psychedelics and entactogens related to positive psychology - the study of healthy human functioning, well-being and eudaemonia. It is an unresolved question how beneficial effects of psychedelics and entactogens are related to the potential risks of these substances - particularly in non-clinical settings. METHODS: We searched in PubMed, PsychINFO and the Cochrane Library for controlled clinical and epidemiological studies which applied concepts from positive psychology. We included N = 77 eligible studies with 9876 participants published before November 1st, 2017: (1) quantitative studies (N = 54), (2) preliminary or exploratory studies and reviews not including meta-analyses (N = 17), and (3) studies evidencing primarily negative results (N = 6). RESULTS: Positive psychology concepts have been applied for measuring effects of clinical trials, recreational and ceremonial use of psychedelics and entactogens. Psychedelics and entactogens were shown to produce acute and long-term effects on mood, well-being, prosocial behaviours, empathy, cognitive flexibility, creativity, personality factors like openness, value orientations, nature-relatedness, spirituality, self-transcendence and mindfulness-related capabilities. CONCLUSIONS: There is preliminary evidence for beneficial effects of psychedelics and entactogens on measures of positive psychology in clinical and healthy populations, however their sustainability remains largely unresolved. The reported results must be considered preliminary due to methodological restrictions. Since longitudinal data on both positive and adverse effects of psychedelics are lacking, more rigorous and standardized measures from positive psychology should be applied in less biased populations with prospective longitudinal designs to carefully assess the benefit-risk-ratio. This article is part of the Special Issue entitled 'Psychedelics: New Doors, Altered Perceptions'.
RATIONALE: We reviewed the concepts and empirical findings in studies with psychedelics and entactogens related to positive psychology - the study of healthy human functioning, well-being and eudaemonia. It is an unresolved question how beneficial effects of psychedelics and entactogens are related to the potential risks of these substances - particularly in non-clinical settings. METHODS: We searched in PubMed, PsychINFO and the Cochrane Library for controlled clinical and epidemiological studies which applied concepts from positive psychology. We included N = 77 eligible studies with 9876 participants published before November 1st, 2017: (1) quantitative studies (N = 54), (2) preliminary or exploratory studies and reviews not including meta-analyses (N = 17), and (3) studies evidencing primarily negative results (N = 6). RESULTS: Positive psychology concepts have been applied for measuring effects of clinical trials, recreational and ceremonial use of psychedelics and entactogens. Psychedelics and entactogens were shown to produce acute and long-term effects on mood, well-being, prosocial behaviours, empathy, cognitive flexibility, creativity, personality factors like openness, value orientations, nature-relatedness, spirituality, self-transcendence and mindfulness-related capabilities. CONCLUSIONS: There is preliminary evidence for beneficial effects of psychedelics and entactogens on measures of positive psychology in clinical and healthy populations, however their sustainability remains largely unresolved. The reported results must be considered preliminary due to methodological restrictions. Since longitudinal data on both positive and adverse effects of psychedelics are lacking, more rigorous and standardized measures from positive psychology should be applied in less biased populations with prospective longitudinal designs to carefully assess the benefit-risk-ratio. This article is part of the Special Issue entitled 'Psychedelics: New Doors, Altered Perceptions'.
Authors: Pavla Chomynová; Rita Kočárová; Filip Kňažek; Michaela Plevková; Barbora Bláhová; Karel Valeš; Viktor Mravčík Journal: Cent Eur J Public Health Date: 2022-09 Impact factor: 1.154
Authors: Simon B Goldberg; Benjamin Shechet; Christopher R Nicholas; Chi Wing Ng; Geetanjali Deole; Zhuofan Chen; Charles L Raison Journal: Psychol Med Date: 2020-11-04 Impact factor: 7.723
Authors: Keri Mans; Hannes Kettner; David Erritzoe; Eline C H M Haijen; Mendel Kaelen; Robin L Carhart-Harris Journal: Front Psychiatry Date: 2021-06-29 Impact factor: 4.157